

Junichi Shoda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2095590/publications.pdf>

Version: 2024-02-01

86
papers

2,863
citations

147726

31
h-index

189801

50
g-index

88
all docs

88
docs citations

88
times ranked

5877
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Exercise on the Oral Microbiota and Saliva of Patients with Non-Alcoholic Fatty Liver Disease. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3470.	1.2	9
2	Prevention of non-alcoholic steatohepatitis by long-term exercise via the induction of phenotypic changes in Kupffer cells of hyperphagic obese mice. <i>Physiological Reports</i> , 2021, 9, e14859.	0.7	6
3	Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD. <i>JHEP Reports</i> , 2021, 3, 100253.	2.6	28
4	Relationships of Dietary Habits and Physical Activity Status with Non-Alcoholic Fatty Liver Disease Featuring Advanced Fibrosis. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8918.	1.2	3
5	The prevalence and clinical implications of pancreatic fat accumulation identified during a medical check-up. <i>Medicine (United States)</i> , 2021, 100, e27487.	0.4	0
6	Effect of a sulforaphane supplement on muscle soreness and damage induced by eccentric exercise in young adults: A pilot study. <i>Physiological Reports</i> , 2021, 9, e15130.	0.7	8
7	Gender difference in development of steatohepatitis in $p62/Sqstm1$ and $Nrf2$ double-knockout mice. <i>Experimental Animals</i> , 2020, 69, 395-406.	0.7	4
8	Clinical and anthropometric characteristics of obese non-alcoholic fatty liver disease subjects in Japan. <i>Hepatology Research</i> , 2020, 50, 1032-1046.	1.8	30
9	Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 659-671.	1.1	15
10	Progressive reduction in skeletal muscle mass to visceral fat area ratio is associated with a worsening of the hepatic conditions of non-alcoholic fatty liver disease. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 495-503.	1.1	25
11	Whole-body vibration for patients with nonalcoholic fatty liver disease: a 6-month prospective study. <i>Physiological Reports</i> , 2019, 7, e14062.	0.7	9
12	Urinary Levels of Titin-N Fragment, a Skeletal Muscle Damage Marker, are Increased in Subjects with Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2019, 9, 19498.	1.6	19
13	Deletion of both $p62$ and $Nrf2$ spontaneously results in the development of nonalcoholic steatohepatitis. <i>Experimental Animals</i> , 2018, 67, 201-218.	0.7	22
14	Skeletal muscle mass to visceral fat area ratio is an important determinant affecting hepatic conditions of non-alcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2018, 53, 535-547.	2.3	60
15	Exercise habituation is effective for improvement of periodontal disease status: a prospective intervention study. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 565-574.	0.9	19
16	High-Intensity Aerobic Exercise Improves Both Hepatic Fat Content and Stiffness in Sedentary Obese Men with Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2017, 7, 43029.	1.6	92
17	<i>Wisteria floribunda</i> agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study. <i>Journal of Gastroenterology</i> , 2017, 52, 218-228.	2.3	12
18	Nuclear factor (erythroid derived 2)-like 2 activation increases exercise endurance capacity via redox modulation in skeletal muscles. <i>Scientific Reports</i> , 2017, 7, 12902.	1.6	51

#	ARTICLE	IF	CITATIONS
19	Exercise training enhances in vivo clearance of endotoxin and attenuates inflammatory responses by potentiating Kupffer cell phagocytosis. <i>Scientific Reports</i> , 2017, 7, 11977.	1.6	25
20	p62 modulates the intrinsic signaling of UVB-induced apoptosis. <i>Journal of Dermatological Science</i> , 2016, 83, 226-233.	1.0	8
21	Verification of WFA-Sialylated MUC1 as a Sensitive Biliary Biomarker for Human Biliary Tract Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 671-677.	0.7	10
22	Inchinkoto and Jaundice. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 207-224.	0.1	1
23	Expression of insulin-like growth factor I receptor as a biomarker for predicting prognosis in biliary tract cancer patients. <i>Molecular and Clinical Oncology</i> , 2015, 3, 464-470.	0.4	7
24	Therapeutic effect of hybrid training of voluntary and electrical muscle contractions in middle-aged obese women with nonalcoholic fatty liver disease: a pilot trial. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 371.	0.9	14
25	Cytoprotective Role of Nrf2 in Electrical Pulse Stimulated C2C12 Myotube. <i>PLoS ONE</i> , 2015, 10, e0144835.	1.1	37
26	Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab. <i>Journal of Gastroenterology</i> , 2015, 50, 467-479.	2.3	32
27	Lectin Microarray-Based Sero-Biomarker Verification Targeting Aberrant <i>O</i> -Linked Glycosylation on Mucin 1. <i>Analytical Chemistry</i> , 2015, 87, 7274-7281.	3.2	46
28	Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: A retrospective study. <i>Hepatology</i> , 2015, 61, 1205-1215.	3.6	126
29	Liver, Muscle, and Insulin Resistance in Obese Subjects: Exercise Effects. <i>Japanese Journal of Physical Fitness and Sports Medicine</i> , 2015, 64, 217-226.	0.0	0
30	Abdominal obesity: causal factor or simply a symptom of obesity-related health risk. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2014, 7, 289.	1.1	7
31	Acceleration training for managing nonalcoholic fatty liver disease: a pilot study. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 925.	0.9	19
32	Targeting Interleukin-4 Receptor Alpha by Hybrid Peptide for Novel Biliary Tract Cancer Therapy. <i>International Journal of Hepatology</i> , 2014, 2014, 1-7.	0.4	7
33	Regular Exercise Coupled to Diet Regimen Accelerates Reduction of Hepatic Steatosis and Associated Pathological Conditions in Nonalcoholic Fatty Liver Disease. <i>Metabolic Syndrome and Related Disorders</i> , 2014, 12, 290-298.	0.5	34
34	Changes in diffusion tensor imaging (DTI) eigenvalues of skeletal muscle due to hybrid exercise training. <i>Magnetic Resonance Imaging</i> , 2014, 32, 1297-1300.	1.0	18
35	Peroxiredoxin I plays a protective role against UVA irradiation through reduction of oxidative stress. <i>Journal of Dermatological Science</i> , 2014, 74, 9-17.	1.0	22
36	Expression of N-acetylglucosaminyltransferase V in the subserosal layer correlates with postsurgical survival of pathological tumor stage 2 carcinoma of the gallbladder. <i>Journal of Gastroenterology</i> , 2014, 49, 702-714.	2.3	5

#	ARTICLE	IF	CITATIONS
37	Interaction of Muc4 and ErbB2 in a transgenic mouse model of gallbladder carcinoma: Potential pathobiological implications. <i>Oncology Reports</i> , 2014, 32, 1796-1802.	1.2	8
38	Negative expression of N-acetylglucosaminyltransferase V in oral squamous cell carcinoma correlates with poor prognosis. <i>SpringerPlus</i> , 2013, 2, 657.	1.2	8
39	Deletion of Nrf2 leads to rapid progression of steatohepatitis in mice fed atherogenic plus high-fat diet. <i>Journal of Gastroenterology</i> , 2013, 48, 620-632.	2.3	70
40	Deficiency of p62/Sequestosome 1 Causes Hyperphagia Due to Leptin Resistance in the Brain. <i>Journal of Neuroscience</i> , 2013, 33, 14767-14777.	1.7	55
41	Exercise Reduces Inflammation and Oxidative Stress in Obesity-Related Liver Diseases. <i>Medicine and Science in Sports and Exercise</i> , 2013, 45, 2214-2222.	0.2	48
42	Nrf2 inhibits hepatic iron accumulation and counteracts oxidative stress-induced liver injury in nutritional steatohepatitis. <i>Journal of Gastroenterology</i> , 2012, 47, 924-935.	2.3	67
43	Biliary tract carcinoma: clinical perspectives on molecular targeting strategies for therapeutic options. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2012, 19, 342-353.	1.4	6
44	Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells. <i>Journal of Gastroenterology</i> , 2011, 46, 779-789.	2.3	43
45	<i>Wisteria floribunda</i> agglutinin-positive mucin 1 is a sensitive biliary marker for human cholangiocarcinoma. <i>Hepatology</i> , 2010, 52, 174-182.	3.6	92
46	Deletion of nuclear factor-E2-related factor-2 leads to rapid onset and progression of nutritional steatohepatitis in mice. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 298, G283-G294.	1.6	132
47	Nrf2 counteracts cholestatic liver injury via stimulation of hepatic defense systems. <i>Biochemical and Biophysical Research Communications</i> , 2009, 389, 431-436.	1.0	75
48	Choleretic effect of inchinkoto, a herbal medicine, on livers of patients with biliary obstruction due to bile duct carcinoma. <i>Hepatology Research</i> , 2009, 39, 247-255.	1.8	18
49	The α -glucosidase inhibitor acarbose prevents obesity and simple steatosis in sequestosome 1/A170/p62 deficient mice. <i>Hepatology Research</i> , 2009, 39, 490-500.	1.8	35
50	Potent <i>in vitro</i> and <i>in vivo</i> antitumor activity of interleukin-4-conjugated <i>Pseudomonas</i> exotoxin against human biliary tract carcinoma. <i>International Journal of Cancer</i> , 2008, 123, 2915-2922.	2.3	15
51	MUC4 interacts with ErbB2 in human gallbladder carcinoma: Potential pathobiological implications. <i>European Journal of Cancer</i> , 2008, 44, 1048-1056.	1.3	38
52	Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 295, G735-G747.	1.6	121
53	Inchinkoto, a herbal medicine, and its ingredients dually exert Mrp2/MRP2-mediated choleresis and Nrf2-mediated antioxidative action in rat livers. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 292, G1450-G1463.	1.6	76
54	Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice. <i>Hepatology Research</i> , 2007, 37, 548-556.	1.8	27

#	ARTICLE	IF	CITATIONS
55	Molecular Pathogenesis of Hepatolithiasis - A Type of Low Phospholipid-Associated Cholelithiasis. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 669.	3.0	17
56	Impaired expression of hepatic multidrug resistance protein 2 is associated with posthepatectomy hyperbilirubinemia in patients with biliary cancer. <i>Langenbeck's Archives of Surgery</i> , 2005, 390, 421-429.	0.8	15
57	Expression of UDP-N-Acetyl- β -D-Galactosamine-Polypeptide N-Acetylgalactosaminyltransferase Isozyme 3 in the Subserosal Layer Correlates with Postsurgical Survival of Pathological Tumor Stage 2 Carcinoma of the Gallbladder. <i>Clinical Cancer Research</i> , 2004, 10, 2090-2099.	3.2	24
58	Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPAR α -mediated redistribution of ABCB4. <i>Journal of Lipid Research</i> , 2004, 45, 1813-1825.	2.0	49
59	Expression of MUC1 recognized by monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of advanced colon carcinoma. <i>Clinical and Experimental Metastasis</i> , 2004, 21, 321-329.	1.7	22
60	Expression of MUC1 recognized by a monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of carcinoma of the gallbladder. <i>Clinical and Experimental Metastasis</i> , 2004, 21, 353-362.	1.7	15
61	Genipin enhances Mrp2 (Abcc2)-mediated bile formation and organic anion transport in rat liver. <i>Hepatology</i> , 2004, 39, 167-178.	3.6	100
62	Mutations identified in the human multidrug resistance P-glycoprotein 3 (ABCB4) gene in patients with primary hepatolithiasis. <i>Hepatology Research</i> , 2004, 29, 160-166.	1.8	21
63	Novel mutations identified in the human multidrug resistance-associated protein 2 (MRP2/ABCC2) gene in a Japanese patient with Dubin-Johnson syndrome. <i>Hepatology Research</i> , 2003, 27, 323-326.	1.8	31
64	Prostaglandin E receptors in bile ducts of hepatolithiasis patients and the pathobiological significance for cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 285-296.	2.4	13
65	Hepatolithiasis-epidemiology and pathogenesis update. <i>Frontiers in Bioscience - Landmark</i> , 2003, 8, e398-409.	3.0	54
66	Prostaglandin E receptors in bile ducts of hepatolithiasis patients and the pathobiological significance for cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 285-296.	2.4	11
67	Prostaglandin E receptors in bile ducts of hepatolithiasis patients and the pathobiological significance for cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 285-96.	2.4	3
68	Expression of cyclooxygenase-2 in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder. <i>International Journal of Cancer</i> , 2002, 98, 427-434.	2.3	26
69	Plasma levels of mevalonate and β -hydroxy-4-cholesten-3-one in chronic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 14, 150-155.	1.4	1
70	Expressions of cyclooxygenase-2 and prostaglandin E-receptors in carcinoma of the gallbladder: crucial role of arachidonate metabolism in tumor growth and progression. <i>Clinical Cancer Research</i> , 2002, 8, 1157-67.	3.2	59
71	Novel murine autoimmune-mediated liver disease model induced by graft-versus-host reaction and concanavalin A. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 1149-1157.	1.4	3
72	Etiologic significance of defects in cholesterol, phospholipid, and bile acid metabolism in the liver of patients with intrahepatic calculi. <i>Hepatology</i> , 2001, 33, 1194-1205.	3.6	59

#	ARTICLE	IF	CITATIONS
73	The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function. <i>American Journal of Gastroenterology</i> , 2001, 96, 3368-3378.	0.2	114
74	Cytokine profile of liver-infiltrating CD4 + T cells separated from murine primary biliary cirrhosis-like hepatic lesions induced by graft-versus-host reaction. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 443-451.	1.4	14
75	Secretory low-molecular-weight phospholipases A2 and their specific receptor in bile ducts of patients with intrahepatic calculi: Factors of chronic proliferative cholangitis. <i>Hepatology</i> , 1999, 29, 1026-1036.	3.6	35
76	Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones: A cohort analysis. <i>Hepatology</i> , 1999, 30, 6-13.	3.6	99
77	Effects of long-term ursodeoxycholate administration on expression levels of secretory low-molecular-weight phospholipases A and mucin genes in gallbladders and biliary composition in patients with multiple cholesterol stones. <i>Hepatology</i> , 1998, 28, 302-313.	3.6	30
78	Multiple regression analysis for assessing the growth of small hepatocellular carcinoma: The MIB-1 labeling index is the most effective parameter. <i>Journal of Gastroenterology</i> , 1998, 33, 229-235.	2.3	19
79	Short-term effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor on cholesterol and bile acid synthesis in humans. <i>Lipids</i> , 1997, 32, 873-878.	0.7	7
80	Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. <i>Journal of Gastroenterology</i> , 1996, 31, 552-558.	2.3	76
81	Increase of deoxycholate in supersaturated bile of patients with cholesterol gallstone disease and its correlation with de novo syntheses of cholesterol and bile acids in liver, gallbladder emptying, and small intestinal transit. <i>Hepatology</i> , 1995, 21, 1291-1302.	3.6	88
82	Randomized control trial of lipo-prostaglandin E1 in patients with acute liver injury induced by Lipiodol-targeted chemotherapy*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 57, 582-589.	2.3	5
83	Primary dual defect of cholesterol and bile acid metabolism in liver of patients with intrahepatic calculi. <i>Gastroenterology</i> , 1995, 108, 1534-1546.	0.6	32
84	Alterations of bile acid composition in gallstones, bile, and liver of patients with hepatolithiasis, and their etiological significance. <i>Digestive Diseases and Sciences</i> , 1993, 38, 2130-2141.	1.1	29
85	Microanalysis of bile acid composition in intrahepatic calculi and its etiological significance. <i>Gastroenterology</i> , 1991, 101, 821-830.	0.6	19
86	Regular Exercise as a Secondary Practical Treatment for Nonalcoholic Fatty Liver Disease. <i>Exercise Medicine</i> , 0, 2, 4.	0.0	7